Emerging Biomarkers May Expand Options for Earlier Autism Identification

The Promise of Objective Screening Tools

For decades, autism has been identified through behavioral observations—a process that often delays recognition until after developmental differences become apparent. Emerging research explores biological markers that could complement existing assessments. A 2026 study in Nature found distinct microbial byproducts (metabolites) in urine and stool samples that associated with some autism presentations, while a 2024 JAMA Network Open study showed eye-tracking measures could be adapted for pediatric offices. Neither approach diagnoses autism alone, but they represent steps toward more accessible identification.

Multiple Approaches Under Investigation

Other developing methods include:

Neither approach diagnoses autism alone, but they represent steps toward more accessible identification.

• Digital movement analysis: AI assessment of infant videos detected movement patterns associated with later autism diagnoses in a 2023 Nature Medicine study (n=124), though replication in larger groups is ongoing
• Combined biomarker panels: Research from CUHK and MicroSigX (2025) reported 82% accuracy in preliminary tests (n=368) using gut bacteria and metabolic markers, but validation across ethnicities remains incomplete
• Early biological signs: A 2025 Journal of Neurochemistry review cataloged brain and physiological differences detectable before behavioral signs emerge, though their predictive value requires longitudinal study

'These tools may eventually help address disparities in early identification,' notes neuroscientist Dr. James Morton in a Frontiers in Neuroscience commentary, 'but we need rigorous trials across genders, racial groups, and co-occurring conditions.'

Implementation Challenges and Ethical Considerations

Key barriers include:

• Heterogeneity: Current biomarkers detect specific autism presentations—for example, the Nature microbial metabolites applied to only 32% of their autistic participants
• Commercialization risks: Direct-to-consumer tests like Japan's ClearStrand-ASD market claims without peer-reviewed validation, warns a 2024 ScienceDirect analysis
• Ethical dilemmas: Presymptomatic detection raises questions about labeling children before support needs are clear, as discussed in Neurology Advisor

'Families deserve transparency about what biomarkers can—and can't—tell us,' emphasizes Morton. 'A positive screen should always lead to comprehensive evaluation, not assumptions.'